# NeoVax Plus Ipilimumab in Renal Cell Carcinoma

> **NCT02950766** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Patrick Ott, MD, PhD** · enrollment: 19 (estimated)

## Conditions studied

- Kidney Cancer

## Interventions

- **DRUG:** NeoVax
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT02950766
- **Lead sponsor:** Patrick Ott, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-03-03
- **Primary completion:** 2027-12-31
- **Final completion:** 2030-05-30
- **Target enrollment:** 19 (ESTIMATED)
- **Last updated:** 2026-02-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02950766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02950766, "NeoVax Plus Ipilimumab in Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02950766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*